Dianthus Therapeutics, Inc. - Common Stock DNTH 深 沪
等待开盘 12-15 09:30:00 美东时间
42.13
+0.500
+1.20%
华盛通- 最 高43.19
- 今 开41.64
- 成交量 52.02万股
- 最 低 40.9758
- 昨 收 41.63
- 总市值 16.77亿
- 52周最高 45.455
- 市盈率 静 --
- 换手率 1.31%
- 52周最低 13.365
- 委 比 -9.05%
- 总股本 3980.44万
- 历史最高 336.00
- 量 比 1.13
- 振 幅 5.32%
- 历史最低 5.136
- 每 手 1
- 风险率 8.02%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调英伟达目标价从210美元升至220美元；DraftKings、DoubleVerify遭多家大行下调目标价
今日重点评级关注：Guggenheim：维持InflaRx"买入"评级，目标价从10美元升至22美元；巴克莱：维持Tandem糖尿病护理"超配"评级，目标价从51美元升至55美元
11-11 10:49
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Wedbush Maintains Outperform on Dianthus Therapeutics, Raises Price Target to $46
Wedbush analyst Laura Chico maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Outperform and raises the price target from $44 to $46.
11-06 21:32
Dianthus Therapeutics Reviews New Data From Phase 2 MaGic Trial Of Claseprubart In Generalized Myasthenia Gravis Presented At AANEM Annual Meeting
Positive data from Phase 2 MaGic trial presented for claseprubart in generalized Myasthenia Gravis, including new open-label extension data further supporting potential for 300mg/2mL Q4W dosingPhase 3 gMG trial planned
10-30 03:32
终于反攻！创新药四季度催化剂密集，港股通创新药ETF(159570)再度涨超1%，近20日“吸金”超13.6亿元！机构：看好创新药长期逻辑！
今日（10.24），受政策面影响市场情绪回暖，港药再度反攻。100%创新药含量的港股通创新药ETF（159570）涨超1%，盘中成交额快速突破8亿元！资金面上...
10-24 10:32
一天三个BD，创新药再掀狂潮！翰森制药逆市涨近4%，BD总额超15.3亿美元！港股通创新药ETF(159570)资金近20日净流入超29亿元！
今日（10.17），在连续两日反攻后，港股通创新药ETF（159570）回调一度超1%，现跌幅收窄至0.38%，盘中成交额快速突破8.6亿元！资金面上，近20日...
10-17 11:13
10亿美元出海，来自今年最火IPO之一
（来源：动脉新医药） 10月16日晚，南京维立志博与Dianthus Therapeutics宣布已就DNTH212（LBL-047）达成独家许可协议。双方达成...
10-17 08:00
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
Dianthus Therapeutics and Nanjing Leads Biolabs have entered into an exclusive licensing agreement for DNTH212, a bifunctional fusion protein targeting BDCA2 and BAFF/APRIL to reduce Type 1 interferon production and suppress B cell function, respectively. DNTH212 has shown superior performance compared to existing therapies, with potential for improved outcomes in severe autoimmune diseases. The FDA has cleared the IND for DNTH212, and Phase 1 st...
10-16 11:00
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Truist Securities Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $56
Truist Securities analyst Danielle Brill initiates coverage on Dianthus Therapeutics (NASDAQ:DNTH) with a Buy rating and announces Price Target of $56.
10-14 21:07
